This inventor holds 4 USPTO granted patents, plus 3 CIPO patents and 1 EPO patent. Top assignee: Aprea Ab. Active years: 2005-2010.
Location History:
- Taby, SE (2005 - 2010)
- Täby, SE (2010)
Company Filing History:
Years Active: 2005-2010
Title: Vladimir Bykov: Innovator in Pharmaceutical Compounds
Introduction
Vladimir Bykov is a notable inventor based in Taby, Sweden. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds aimed at treating various diseases. With a total of 4 patents to his name, Bykov's work focuses on innovative solutions for complex medical challenges.
Latest Patents
Among his latest patents, Bykov has developed Azabicyclooctan-3-one derivatives and their applications. These compounds are designed for use in pharmaceutical compositions targeting hyperproliferative diseases, such as cancer, autoimmune diseases, and heart disease. Another significant invention involves low molecular weight compounds that can reactivate the apoptosis-inducing function of mutant p53 proteins. This reactivation is crucial for restoring the sequence-specific DNA-binding activity and transcriptional transactivation function of these proteins, which can lead to effective treatments for various types of tumors.
Career Highlights
Bykov is currently associated with Aprea AB, a company dedicated to advancing cancer therapies. His work at Aprea AB emphasizes the importance of innovative pharmaceutical solutions and the potential for new treatments that can significantly impact patient outcomes.
Collaborations
Some of his notable coworkers include Galina Selivanova and Klas Wiman, who contribute to the collaborative efforts in research and development within the company.
Conclusion
Vladimir Bykov's contributions to pharmaceutical innovations highlight his commitment to addressing critical health issues through scientific research. His patents reflect a deep understanding of complex biological mechanisms and a dedication to improving treatment options for patients.